Filters
Findings from the phase III ELATIVE® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.
Growth hormone therapy appears to boost height and growth rate in girls with Turner Syndrome (TS) or growth hormone deficiency (GHD), with pronounced effect seen in the first year of treatment, according to a case-control study.
Women with opioid use disorder (OUD) treated with buprenorphine during pregnancy had significantly lower rates of adverse maternal and infant outcomes than those who did not receive treatment, according to a study presented at PAS 2025.
In critically ill patients with moderate-to-severe acute respiratory distress syndrome (ARDS), inhaled sedation with sevoflurane may lead to fewer ventilator-free days at day 28 and lower 90-day survival compared with sedation with propofol, according to the results of the phase III SESAR study.
In Singaporean women, improved physical performance appears to reduce the risk of depression during midlife, whereas worsening menopausal symptoms and pelvic floor dysfunction contribute to a risk increase, according to a local study.
During early pregnancy, high levels of maternal estradiol (E2) appear to contribute to altered glucose metabolism and greater metabolic risks in children conceived via in vitro fertilization (IVF), reports a recent study.
A recent study in Singapore that profiled workers in four various industries has found several health issues, such as smoking, stress, poor dietary habits, and physical inactivity.
IBP-9414, a live biotherapeutic product (LBP), delivers gastrointestinal (GI) and mortality benefits in very low birth weight (VLBW) infants (BW 500–1,500g) born between 23 and 32 weeks gestational age in the phase III Connection study presented at PAS 2025.
Dietary intake of polyunsaturated fatty acids (PUFAs) helps reduce the risk of rheumatoid arthritis (RA), as reported in a study.
New drug applications approved by US FDA as of 16-30 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
